AxoGen Inc (OQ:AXGN)

Business Focus: Advanced Medical Equipment & Technology

Apr 16, 2024 07:00 am ET
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the...
Mar 05, 2024 07:00 am ET
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31,...
Feb 13, 2024 04:30 pm ET
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024,...
Feb 02, 2024 04:15 pm ET
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment...
Jan 18, 2024 05:00 pm ET
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of...
Jan 04, 2024 04:45 pm ET
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2023 revenue. Preliminary Unaudited Fourth...
Jan 04, 2024 04:40 pm ET
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that President and Chief Executive Officer (CEO) Karen Zaderej plans to retire from the Company by...
Jan 04, 2024 04:35 pm ET
Axogen Announces Promotions on Research and Development Team
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the promotions of three research and development team members. The promotions are: Erick...
Dec 26, 2023 04:15 pm ET
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December...
Dec 06, 2023 07:00 am ET
Axogen Announces Transition of Finance Team Leadership
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Mr. Nir Naor as Chief Financial Officer, effective immediately. A senior...
Dec 01, 2023 05:00 pm ET
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment...
Nov 20, 2023 07:00 am ET
Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will present at the Piper...
Nov 07, 2023 07:00 am ET
Axogen, Inc. Reports 2023 Third Quarter Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2023. Third...
Oct 18, 2023 07:00 am ET
Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the...
Sep 05, 2023 07:00 am ET
Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the full launch of Axoguard HA+ Nerve Protector. “Axoguard HA+ is an important extension of our...
Aug 31, 2023 07:00 am ET
Axogen to Participate at Upcoming Investor Conferences
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will participate in two...
Aug 21, 2023 07:00 am ET
Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the successful first week of processing for Avance Nerve Graft at the newly opened Axogen...
Aug 07, 2023 04:01 pm ET
Axogen, Inc. Reports 2023 Second Quarter Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2023. Second...
Jul 27, 2023 07:00 am ET
Axogen to Participate at Canaccord Genuity’s 43rd Annual Growth Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will participate in a...
Jul 26, 2023 07:00 am ET
Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2023 financial results on Monday, August 7, 2023 after the...
May 24, 2023 07:00 am ET
Axogen to Participate at Jefferies Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will participate in a...
May 12, 2023 07:00 am ET
Axogen to Participate at JMP Securities Life Sciences Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Peter Mariani, Executive Vice President & Chief Financial Officer, will participate in a...
May 09, 2023 07:00 am ET
Axogen, Inc. Reports 2023 First Quarter Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2023. First...
Apr 18, 2023 04:05 pm ET
Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 before the market...
Mar 14, 2023 07:00 am ET
Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31,...
Mar 06, 2023 07:00 am ET
Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Marc Began as Executive Vice President. Additionally, effective March 20, 2023,...
Mar 02, 2023 04:00 pm ET
Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter 2022 financial results on Tuesday, March 14, 2023 before the...
Feb 13, 2023 07:00 am ET
Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jens Schroeder Kemp to the newly created role of Chief Marketing Officer. Kemp...
Jan 09, 2023 07:00 am ET
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2022 revenue. Preliminary Unaudited Fourth...
Jan 05, 2023 07:00 am ET
Axogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-reviewed studies of Allograft, Autograft, and Conduits
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the independent publication of a comprehensive, retrospective clinical review comparing the...
Jan 04, 2023 07:00 am ET
Axogen to Participate at J.P. Morgan 41st Annual Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JP Morgan 41st Annual...
Dec 19, 2022 07:00 am ET
Axogen Patient to Ride the 2023 Donate Life Rose Parade® Float Supporting awareness of organ and tissue donation
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Bri Majsiak, a Resensation® patient, has been selected to ride on the 2023 Donate Life Rose...
Nov 08, 2022 07:00 am ET
Axogen, Inc Reports 2022 Third Quarter Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2022. Third...
Nov 03, 2022 04:00 pm ET
Axogen to Participate at Upcoming Investor Conferences
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, and Peter Mariani, executive vice president and...
Oct 31, 2022 07:00 am ET
Axogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that effective December 13, 2022 (the “Effective Date”), Adrian Tyndall, M.D., MPH, FACEP has been...
Oct 20, 2022 07:00 am ET
Axogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022 before the...
Sep 22, 2022 07:00 am ET
Axogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that it will participate in the 77th Annual Meeting of the American Society for...
Aug 03, 2022 04:01 pm ET
Axogen, Inc Reports 2022 Second Quarter Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2022. Second...
Jul 29, 2022 07:00 am ET
Axogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at Canaccord Genuity's 42nd Annual...
Jul 18, 2022 04:00 pm ET
Axogen, Inc. Announces Organizational Updates, Preliminary Second Quarter Revenue and Reaffirms Full-Year 2022 Financial Guidance
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced organizational updates and preliminary second quarter revenue. The company is making certain...
Jul 11, 2022 07:00 am ET
Axogen, Inc. Appoints William Burke to Board of Directors
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that, effective July 11, 2022, William Burke has been appointed to its Board of Directors and will...
May 18, 2022 07:00 am ET
Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president and Peter J. Mariani, executive vice president...
May 04, 2022 04:05 pm ET
Axogen, Inc Reports 2022 First Quarter Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2022. First...
May 04, 2022 04:01 pm ET
Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced topline results from its RECON Clinical Study comparing Avance Nerve Graft to conduits in digital...
Apr 13, 2022 07:00 am ET
Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022 after the...
Mar 17, 2022 07:00 am ET
Axogen, Inc. publishes inaugural ESG Report
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today published its inaugural Environmental, Social, and Governance (ESG) report highlighting the company’s...
Feb 24, 2022 08:31 am ET
Thinking about buying stock in Harmony Gold Mining, Clover Health, Sundial Growers, AxoGen, or Hecla Mining?
NEW YORK, Feb. 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HMY, CLOV, SNDL, AXGN, and HL.
Feb 22, 2022 04:34 pm ET
Axogen, Inc. Reports 2021 Fourth Quarter and Full-Year Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31,...
Feb 03, 2022 07:00 am ET
Axogen to Participate at Upcoming Investor Conferences
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced it will participate in two investor conferences in February. Karen Zaderej, chairman, CEO, and...
Feb 02, 2022 07:00 am ET
Axogen, Inc. to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on February 22, 2022
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter and full-year 2021 financial results on Tuesday, February 22,...
Jan 12, 2022 08:31 am ET
Thinking about buying stock in Avalo Therapeutics, AxoGen, Ocugen, BioNano Genomics, or Aurora Innovation?
NEW YORK, Jan. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVTX, AXGN, OCGN, BNGO, and AUR.
Jan 10, 2022 07:00 am ET
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2021 revenue. Preliminary Unaudited Fourth...
Jan 04, 2022 07:00 am ET
Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2022 meetings of the American Association for...
Dec 15, 2021 07:00 am ET
Axogen sponsors 2022 Donate Life Rose Parade® Float to help raise awareness of organ and tissue donation
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today that nerve repair patient Christopher (Chris) Brown has been selected to ride on...
Nov 10, 2021 07:00 am ET
Axogen, Inc. to Participate at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Canaccord Genuity Virtual...
Nov 04, 2021 07:00 am ET
Axogen, Inc. to Participate at Jefferies London Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO and president, will present at the Jefferies London Healthcare...
Nov 03, 2021 04:01 pm ET
Axogen, Inc. Reports 2021 Third Quarter Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2021. Third...
Oct 13, 2021 07:00 am ET
Axogen, Inc. to Report Third Quarter Financial Results and Host Conference Call on November 3, 2021
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report third quarter 2021 financial results on Wednesday, November...
Sep 22, 2021 07:00 am ET
Axogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that it will participate in the 76th Annual Meeting of the American Society for...
Sep 01, 2021 07:00 am ET
Axogen RECON(SM) Clinical Study Completes Subject Follow-up
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that the RECON Clinical Study supporting its Biologics License Application...
Aug 04, 2021 04:01 pm ET
Axogen, Inc. Reports 2021 Second Quarter Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2021. Second...
Jul 22, 2021 07:00 am ET
Axogen, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Canaccord...
Jul 19, 2021 04:01 pm ET
Axogen, Inc. Appoints John H. Johnson to Board of Directors
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that John H. Johnson has been appointed to its Board of Directors, effective...
Jul 14, 2021 07:00 am ET
Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2021 financial results on Wednesday, August 4,...
May 18, 2021 07:00 am ET
Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president and Peter J. Mariani,...
May 06, 2021 07:00 am ET
Axogen, Inc. to Present at the Canaccord Genuity Musculoskeletal Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Peter J. Mariani, executive vice president and chief financial officer...
May 05, 2021 04:00 pm ET
Axogen, Inc. Reports 2021 First Quarter Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2021. First...
Apr 14, 2021 07:00 am ET
Axogen, Inc. to Report First Quarter Financial Results and Host Conference Call on May 5, 2021
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2021 financial results on Wednesday, May 5,...
Mar 01, 2021 04:01 pm ET
Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President and Chief Financial Officer
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the promotion of Peter J. Mariani to Executive Vice President and Chief Financial Officer. Mr....
Feb 22, 2021 04:01 pm ET
Axogen, Inc. Reports 2020 Fourth Quarter and Full-Year Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31,...
Feb 18, 2021 07:00 am ET
Axogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced completion of pilot phase analysis for its REPOSE clinical study.  Analysis of...
Feb 04, 2021 07:00 am ET
Axogen, Inc. to Participate at Upcoming February Investor Conferences
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced it will participate in two investor conferences in February. Karen Zaderej,...
Feb 01, 2021 07:00 am ET
Axogen, Inc. to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call on February 22, 2021
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report fourth quarter and full-year 2020 financial results on...
Jan 11, 2021 07:00 am ET
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2020
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2020 revenue. Preliminary Unaudited Fourth...
Jan 05, 2021 07:00 am ET
Axogen to Participate at AAHS ASPN ASRM 2021 Virtual Annual Meetings
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2021 meetings of the American Association for...
Dec 23, 2020 07:00 am ET
Axogen Sponsors Donate Life at 2021 Virtual Rose Parade Celebration
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today their sponsorship of Donate Life at the annual Tournament of Roses® celebration....
Nov 04, 2020 07:00 am ET
Axogen, Inc. to Participate at Jefferies Virtual London Healthcare Conference and Canaccord Genuity Virtual MedTech & Diagnostics Forum
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at two upcoming...
Oct 29, 2020 04:01 pm ET
Axogen, Inc. Reports Third Quarter 2020 Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended September 30, 2020....
Oct 08, 2020 07:00 am ET
Axogen, Inc. to Report Third Quarter 2020 Financial Results and Host Conference Call on October 29, 2020
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report third quarter 2020 financial results on Thursday, October 29,...
Sep 30, 2020 04:01 pm ET
Axogen, Inc. Appoints Paul G. Thomas to Board of Directors
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Paul G. Thomas has been appointed to its Board of Directors, effective...
Sep 25, 2020 07:00 am ET
Axogen, Inc. to Present at the JMP Securities MedTech Bio Summit
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JMP...
Sep 24, 2020 07:00 am ET
Axogen to Participate in the 75th Annual American Society for Surgery of the Hand Meeting
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that it will participate in the 75th Annual Meeting of the American Society for...
Aug 31, 2020 07:00 am ET
Axogen, Inc. to Present at the Cantor Virtual Global Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Cantor...
Aug 05, 2020 04:01 pm ET
Axogen, Inc. Reports Second Quarter 2020 Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2020. Second...
Jul 29, 2020 07:00 am ET
Axogen, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Canaccord...
Jul 22, 2020 07:00 am ET
Axogen RECON Clinical Study Completes Target Enrollment of 220 Subjects
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that its phase 3 pivotal RECONSM Clinical Study supporting its Biologics License...
Jul 15, 2020 07:00 am ET
Axogen, Inc. to Report Second Quarter 2020 Financial Results and Host Conference Call on August 5, 2020
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report second quarter 2020 financial results on Wednesday, August 5,...
Jul 01, 2020 07:00 am ET
Axogen Announces New Seven-Year Financing Agreement with Oberland Capital and Provides Preliminary Second Quarter Revenue Estimate
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced a financing agreement with Oberland Capital and provided preliminary, estimated revenue for the...
Jun 01, 2020 07:00 am ET
Axogen, Inc. Announces Planned Retirement of Greg Freitag and Appoints Brad Ottinger as General Counsel and Chief Compliance Officer
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced the appointment of Brad Ottinger as General Counsel and Chief Compliance...
May 20, 2020 07:00 am ET
Axogen, Inc. to Present at the Jefferies Virtual Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Jefferies...
May 06, 2020 04:01 pm ET
Axogen, Inc. Reports First Quarter 2020 Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2020. First...
Apr 23, 2020 07:00 am ET
Axogen, Inc. Reports Preliminary Revenue for the First Quarter 2020, Provides Business Update in Response to COVID-19 Pandemic, and Announces Dismissal of Class Action Lawsuit
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary first quarter 2020 revenue, provided a business update on its actions in response to...
Apr 15, 2020 07:00 am ET
Axogen, Inc. to Report First Quarter 2020 Financial Results and Host Conference Call on May 6, 2020
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2020 financial results on Wednesday, May 6,...
Mar 02, 2020 07:00 am ET
Axogen, Inc. to Participate at Upcoming Investor Conferences
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that members of its management team will participate in two investor...
Feb 24, 2020 04:01 pm ET
Axogen, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31,...
Feb 05, 2020 07:00 am ET
Axogen, Inc. to Present at the Leerink Partners 9th Annual Global Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Leerink...
Feb 03, 2020 07:00 am ET
Axogen, Inc. to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call on February 24, 2020
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report fourth quarter and full-year 2019 financial results on...
Jan 13, 2020 07:00 am ET
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2019 and Provides 2020 Annual Guidance
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2019 revenue. Preliminary Unaudited Fourth...
Jan 08, 2020 07:00 am ET
Axogen Sponsored RANGER® Registry Reaches 2,000 Nerve Repair Enrollment Milestone
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that its RANGER registry enrollment has reached the milestone of 2,000 nerve...
Jan 02, 2020 04:01 pm ET
Axogen to Participate at AAHS ASPN ASRM 2020 Annual Meetings
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2020 meetings of the American Association for...
Jan 02, 2020 07:00 am ET
Axogen, Inc. to Participate at JP Morgan 38th Annual Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JP Morgan...
Dec 18, 2019 07:00 am ET
Axogen awarded research grant from the Advanced Regenerative Manufacturing Institute
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced it has been awarded a grant to research and develop an automated bioprocessing...
Dec 04, 2019 07:00 am ET
Avance® Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade® Float
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced Jessica de Paz has been selected to ride on the 2020 Donate Life Rose Parade...
Nov 21, 2019 07:00 am ET
Axogen, Inc. to Participate at Piper Jaffray 31st Annual Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Piper...
Nov 11, 2019 07:00 am ET
Axogen, Inc. to Participate at Jefferies London Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Jefferies...
Nov 06, 2019 04:04 pm ET
Axogen, Inc. Reports 2019 Third Quarter Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today reported financial results and business highlights for the third quarter ended September...
Oct 23, 2019 07:00 am ET
Axogen, Inc. to Report Third Quarter 2019 Financial Results and Host Conference Call on November 6, 2019
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report third quarter 2019 financial results on Wednesday, November...
Oct 03, 2019 01:40 pm ET
Scott+Scott Attorneys at Law LLP Investigating Axogen, Inc.'s Directors and Officers for Breach of Fiduciary Duties - AXGN
NEW YORK, Oct. 3, 2019 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Axogen, Inc. ("Axogen") (NASDAQ: AXGN) breached their fiduciary duties to Axogen and its shareholders.  If you are an Axogen shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or [email protected].
Sep 19, 2019 07:00 am ET
Axogen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, chief executive officer, and president, will...
Sep 11, 2019 08:00 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Mammoth Energy, Acer Therapeutics, Realogy Holdings, and AxoGen and Encourages Investors to Contact the Firm
Bragar Eagel & Squire is investigating certain officers and directors of Mammoth Energy Services, Inc. (NASDAQ: TUSK), Acer Therapeutics, Inc. (NASDAQ: ACER), Realogy Holdings Corp. (NYSE: RLGY), and AxoGen, Inc. (AXGN) on behalf of long-term...
Aug 27, 2019 07:00 am ET
Axogen to Participate in the 74th Annual American Society for Surgery of the Hand Meeting
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that it will participate in the 74th Annual Meeting of the American Society for...
Aug 14, 2019 09:02 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Lannett, Molson Coors, AxoGen, and American Renal Associates and Encourages Investors to Contact the Firm
Bragar Eagel & Squire is investigating certain officers and directors of Lannett Company, Inc. (NYSE: LCI), Molson Coors Brewing Company (NYSE: TAP), AxoGen, Inc. (NASDAQ: AXGN), and American Renal Associates Holdings, Inc. (NYSE: ARA) on behalf of...
Aug 14, 2019 01:55 pm ET
Shareholder Alert: Robbins Arroyo LLP Announces Complaint Filed Against AxoGen, Inc. (AXGN)
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of AxoGen, Inc. (NYSE: AXGN) filed a derivative complaint against the company's officers and directors for breaches of fiduciary duty beginning November 16, 2017. AxoGen provides surgical intervention for physical damage for peripheral nerve impairments.
Aug 06, 2019 04:01 pm ET
Axogen, Inc. Reports 2019 Second Quarter Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today reported financial results and business highlights for the second quarter ended June 30,...
Jul 29, 2019 07:00 am ET
Axogen, Inc. to Participate at Canaccord Genuity 39th Annual Growth Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Peter J. Mariani, chief financial officer, will present at the Canaccord...
Jul 26, 2019 07:50 am ET
(AXGN) Alert: Johnson Fistel, LLP Announces Investigation of AxoGen, Inc.; Long Term Investors Encouraged to Contact Firm
SAN DIEGO, July 26, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by AxoGen, Inc. ("AxoGen") (NASDAQ: AXGN) and certain of its officers.
Jul 26, 2019 07:00 am ET
Axogen Announces Publication of the 100th Peer-Reviewed Clinical Paper Featuring its Product Portfolio for Peripheral Nerve Repair
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced publication of the 100th peer-reviewed paper featuring results from clinical...
Jul 23, 2019 07:00 am ET
Axogen, Inc. to Report Second Quarter 2019 Financial Results and Host Conference Call on August 6, 2019
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2019 financial results on Tuesday, August 6,...
Jul 22, 2019 06:44 pm ET
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of AxoGen (NASDAQ: AXGN) and Encourages AxoGen Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of AxoGen (NASDAQ: AXGN). According to the complaint filed on July 19, 2019, throughout the class period defendants made materially false and/or...
Jul 19, 2019 12:09 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of AxoGen, Inc. - AXGN
Levi & Korsinsky announces it has commenced an investigation of AxoGen, Inc. (NASDAQCM: AXGN) concerning possible breaches of fiduciary duty. To obtain additional information, go to: http://www.zlkdocs.com/AXGN-Info-Request-Form-7739 or contact...
May 23, 2019 07:00 am ET
Axogen, Inc. to Participate at Upcoming Investor Conferences
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that members of its management team will participate in three upcoming investor...
May 08, 2019 04:01 pm ET
Axogen, Inc. Reports 2019 First Quarter Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today reported financial results and business highlights for the first quarter ended March 31,...
May 02, 2019 07:00 am ET
Axogen, Inc. Appoints New Members to Board of Directors
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced it increased the size of its Board of Directors to nine members and appointed...
Apr 22, 2019 07:01 am ET
Axogen, Inc. Announces Completion of Planned Interim Analysis and One-Time Enrollment Expansion for RECON® Study
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced completion of the planned blinded interim analysis for its RECON Study. The study...
Apr 22, 2019 07:00 am ET
Axogen, Inc. to Report First Quarter 2019 Financial Results and Host Conference Call on May 8, 2019
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2019 financial results on Wednesday, May 8,...
Mar 20, 2019 11:54 am ET
Robbins Arroyo LLP: AxoGen, Inc. (AXGN) Misled Shareholders According to Class Action
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of AxoGen, Inc. (NASDAQ: AXGN) filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1933 and Securities Act of 1934 pursuant to the company's November 2017 Secondary Public
Mar 11, 2019 11:19 am ET
CLASS ACTION UPDATE for AXGN, MKL, VALE and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 10, 2019 10:50 pm ET
AXOGEN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against AxoGen, Inc. - AXGN
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit against AxoGen, Inc. (NasdaqCM: AXGN). Investor losses must relate to purchases of the Company’s securities in connection with its November 2017 or May 2018 secondary public offering or between August 7, 2017 and December 18, 2018. This action is pending in the United States District Court for the Middle District of Florida.
Mar 10, 2019 06:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AxoGen, Markel, Maxar, and Wirecard and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of AxoGen, Inc., Markel Corporation, Maxar Technologies Ltd., and Wirecard AG.  Stockholders have until the deadlines listed...
Mar 08, 2019 10:50 pm ET
AXOGEN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Actio
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit against AxoGen, Inc. (NasdaqCM: AXGN). Investor losses must relate to purchases of the Company’s securities in connection with its November 2017 or May 2018 secondary public offering or between August 7, 2017 and December 18, 2018. This action is pending in the United S
Mar 08, 2019 09:30 pm ET
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AxoGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AxoGen, Inc. (“AxoGen” or “the Company”) (NASDAQ: AXGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...
Mar 08, 2019 06:07 pm ET
KESSLER TOPAZ MELTZER & CHECK, LLP:  Final Deadline Reminder for AXOGEN, INC. Investors – AXGN
Kessler Topaz Meltzer & Check, LLP reminds AxoGen, Inc. (Nasdaq:  AXGN) (“AxoGen”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Middle District of Florida on behalf of purchasers...
Mar 07, 2019 07:54 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AxoGen, Inc. - AXGN
Pomerantz LLP is investigating claims on behalf of investors of AxoGen, Inc. (“AxoGen or the “Company”) (NASDAQ:  AXGN).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Mar 07, 2019 01:58 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AXGN, ATVI, CTL and INGN
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 07, 2019 01:39 pm ET
(AXGN) AxoGen, Inc. - Bronstein, Gewirtz & Grossman, LLC Announces Deadline - March 11, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AxoGen, Inc. ("AxoGen" or the “Company") (NASDAQ: AXGN) and certain of its officers, on behalf of shareholders who...
Mar 07, 2019 11:00 am ET
Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against Axogen, Inc. and March 11 Lead Plaintiff Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Axogen, Inc. (“Axogen” or the “Company”) (NASDAQ: AXGN) and other defendants, related to alleged violations of fe
Mar 07, 2019 10:55 am ET
AXGN EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against AxoGen, Inc. – AXGN
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AxoGen, Inc. (NASDAQ: AXGN): (1) pursuant and/or traceable to the false and/or misleading registration...
Mar 06, 2019 10:02 am ET
SHAREHOLDER ALERT: AXGN GSM MU TYME: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 05, 2019 07:41 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AxoGen, Inc. (AXGN)
Law Offices of Howard G. Smith reminds investors of the March 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN) securities: (a)...
Mar 05, 2019 10:26 am ET
CLASS ACTION UPDATE for AXGN, ATVI, GSM and VALE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 05, 2019 08:25 am ET
New Research Coverage Highlights Advance Auto Parts, AxoGen, Encana, Federal Signal, Nelnet, and Esperion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Advance Auto Parts, Inc. (NYSE:AAP), AxoGen, Inc. (NASDAQ:AXGN), Encana...
Mar 04, 2019 06:37 pm ET
INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against AxoGen, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds AxoGen, Inc. (Nasdaq: AXGN) (“AxoGen”) investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of AxoGen securities: 1) pursuant and/or traceable to the November 2017 SPO; and/or 2) pursuant and/or traceable to the May 2018 SPO; and/or 3) between August 2, 2017 and December 18, 2018, inclusive (the “Class Period”).
Mar 04, 2019 06:29 pm ET
Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against AxoGen, Inc. 
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the March 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN) securities...
Mar 04, 2019 04:18 pm ET
AXGN REMINDER: Zhang Investor Law Reminds Investors of the March 11 Deadline in Securities Class Action Lawsuit Against AxoGen, Inc. – AXGN
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of AxoGen, Inc. (NASDAQ: AXGN): (1) pursuant and/or traceable to the false and/or misleading registration statement and prospectus issued...
Mar 04, 2019 11:54 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AXGN, ATVI and GSM
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Mar 04, 2019 07:00 am ET
Axogen, Inc. to Participate at Upcoming March Investor Conferences
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that members of its management team will participate in three investor...
Mar 03, 2019 06:15 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AxoGen, Markel, Maxar, and Wirecard and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of AxoGen, Inc., Markel Corporation, Maxar Technologies Ltd. and Wirecard AG.  Stockholders have until the deadlines listed below...
Mar 02, 2019 03:15 pm ET
AXOGEN EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against AxoGen, Inc. -- AXGN
NEW YORK, March 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AxoGen, Inc. (NASDAQ: AXGN): (1) pursuant and/or traceable to the false and/or misleading registration statement and prospectus issued in connection with AxoGen's November 2017 secondary public offering; and/or (2) purchased or otherwise acquired AxoGen securities pursuant and/or traceable to AxoGen's false and/or misleading registration statement and prospectus issued in connection with AxoGen's May 2018 second
Mar 01, 2019 10:50 pm ET
AXOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AxoGen, Inc. - AXGN
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit against AxoGen, Inc. (NasdaqCM: AXGN), if they purchased the...
Mar 01, 2019 04:07 pm ET
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against AxoGen, Inc. – AXGN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of AxoGen, Inc. (NASDAQ: AXGN): (1) pursuant and/or traceable to the false and/or misleading registration statement and prospectus...
Mar 01, 2019 11:35 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AXGN, YRIV, W and ATVI
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 01, 2019 07:50 am ET
Market Trends Toward New Normal in Conagra Brands, Camden Property Trust, AxoGen, Tupperware Brands, Preferred Apartment Communities, and Dorman Products — Emerging Consolidated Expectations, Analyst
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Conagra Brands Inc. (NYSE:CAG), Camden Property Trust (NYSE:CPT),...
Feb 28, 2019 03:25 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AxoGen, Inc. - AXGN
Pomerantz LLP is investigating claims on behalf of investors of AxoGen, Inc. (“AxoGen or the “Company”) (NASDAQ:  AXGN).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Feb 28, 2019 12:37 pm ET
SHAREHOLDER ALERT: SOGO AXGN W DPLO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Feb 27, 2019 07:56 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AxoGen, Inc. (AXGN)
Law Offices of Howard G. Smith reminds investors of the March 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN) securities: (a)...
Feb 27, 2019 02:57 pm ET
CLASS ACTION UPDATE for ARLO, AXGN, MAXR and KHC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 27, 2019 01:38 pm ET
Axogen Class Action Lawsuit: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Axogen, Inc. – AXGN
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of AxoGen, Inc. (“AxoGen” or the “Company”)...
Feb 27, 2019 12:50 pm ET
CLASS ACTION UPDATE for AXGN, MU, ASTE and KHC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 26, 2019 06:47 pm ET
Kessler Topaz Meltzer & C, LLP - Important Deadline Reminder for AxoGen, Inc. Investors
The law firm of Kessler Topaz Meltzer & Check, LLP reminds AxoGen, Inc. (Nasdaq:  AXGN) (“AxoGen”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Middle District of Florida against...
Feb 26, 2019 06:07 pm ET
CLASS ACTION UPDATE for YRCW, AXGN, ASTE and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 26, 2019 04:01 pm ET
Axogen, Inc. Reports 2018 Fourth Quarter and Full Year 2018 Financial Results
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today reported financial results and business highlights for the fourth quarter and full year...
Feb 26, 2019 11:38 am ET
CLASS ACTION UPDATE for ARLO, AXGN, CAG and CVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 26, 2019 08:30 am ET
AXGN CLASS ACTION REMINDER: Hagens Berman Reminds AxoGen (NASDAQ: AXGN) Investors of March 11, 2019 Lead Plaintiff Deadline and Possible Accounting Irregularities
SAN FRANCISCO, Feb. 26, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in Axogen, Inc. (NASDAQ: AXGN) of the March 11, 2019 Lead Plaintiff deadline in the pending securities class action.  If you purchased or otherwise acquired AxoGen securities between August 7, 2017 and December 18, 2018 (the "class period") and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit:
Feb 25, 2019 05:38 pm ET
CLASS ACTION UPDATE for AXGN, MAXR, TYME and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 25, 2019 02:31 pm ET
CLASS ACTION UPDATE for AXGN, UXIN and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 25, 2019 11:34 am ET
CLASS ACTION UPDATE for YOGA, AXGN, TAP and BRS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 24, 2019 07:20 pm ET
CLASS ACTION UPDATE for YRCW, AXGN, MAXR and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 24, 2019 06:08 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AxoGen, Markel, Maxar, and Wirecard and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of AxoGen, Inc., Markel Corporation, Maxar Technologies Ltd. and Wirecard AG.  Stockholders have until the deadlines listed below...
Feb 24, 2019 01:50 pm ET
CLASS ACTION UPDATE for AXGN, DXC, MKL and VALE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 24, 2019 10:45 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AXGN, DXC, MAXR and BRS
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Feb 22, 2019 10:50 pm ET
AXOGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Axo
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit against...
Feb 22, 2019 05:25 pm ET
CLASS ACTION UPDATE for SOGO, AXGN, ASTE and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 22, 2019 02:01 pm ET
CLASS ACTION UPDATE for DBVT, AXGN, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 22, 2019 11:50 am ET
CLASS ACTION UPDATE for YRCW, PRGO, AXGN and VALE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 22, 2019 07:05 am ET
CLASS ACTION UPDATE for AXGN, DXC, ATVI and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 21, 2019 05:45 pm ET
CLASS ACTION UPDATE for AXGN, ALKS, GE and BRS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 21, 2019 04:59 pm ET
CLASS ACTION UPDATE for SOGO, AXGN, W and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 21, 2019 04:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AxoGen, Inc. - AXGN
Pomerantz LLP is investigating claims on behalf of investors of AxoGen, Inc. (“AxoGen or the “Company”) (NASDAQ: AXGN).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Feb 21, 2019 01:57 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SOGO, PRGO, AXGN and GE
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Feb 21, 2019 11:17 am ET
CLASS ACTION UPDATE for DNKEY, SOGO, AXGN and MAXR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 21, 2019 07:25 am ET
Research Report Identifies Netflix, Fortive, CareTrust REIT, World Acceptance, AxoGen, and Willis Towers Watson Public with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Netflix, Inc. (NASDAQ:NFLX), Fortive Corporation (NYSE:FTV), CareTrust...
Feb 20, 2019 07:32 pm ET
CLASS ACTION UPDATE for PRGO, AXGN, MKL and MAXR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 20, 2019 02:56 pm ET
AXGN REMINDER NOTICE: Rosen Law Firm Reminds AxoGen, Inc. Investors of Important Deadline in Securities Class Action Lawsuit
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AxoGen, Inc. (NASDAQ:AXGN): (1) pursuant and/or traceable to the false and/or misleading registration statement and prospectus issued in connection with AxoGen’s November 2017 secondary public offering; and/or (2) purchased or otherwise acquired AxoGen securities pursuant and/or traceable to AxoGen’s false and/or misleading registration statement and prospectus issued in connection with AxoGen’s May 2018 secondary public offering; and/or (3) purchased or o
Feb 20, 2019 02:17 pm ET
CLASS ACTION UPDATE for AXGN, VALE, UXIN and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 20, 2019 12:17 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AXGN, ALKS, MU and TAP
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Feb 20, 2019 09:52 am ET
CLASS ACTION UPDATE for IMMU, AXGN, ATVI and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 19, 2019 06:21 pm ET
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for AxoGen, Inc. Investors
The law firm of Kessler Topaz Meltzer & Check, LLP reminds AxoGen, Inc. (Nasdaq:  AXGN) (“AxoGen”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Middle District of Florida against...
Feb 19, 2019 01:20 pm ET
CLASS ACTION UPDATE for YRCW, AXGN and MKL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 19, 2019 07:00 am ET
Axogen, Inc. to Participate at Upcoming February Investor Conferences
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that members of its management team will participate in two investor...
Feb 18, 2019 02:30 pm ET
CLASS ACTION UPDATE for SOGO, AXGN, SVXY and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 18, 2019 06:00 am ET
CLASS ACTION UPDATE for AXGN, TYME, UXIN and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 17, 2019 03:15 pm ET
CLASS ACTION UPDATE for XRAY, AXGN, YRIV and VALE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 17, 2019 01:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AxoGen, Markel, Maxar, and Wirecard and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of AxoGen, Inc., Markel Corporation, Maxar Technologies Ltd. and Wirecard AG.  Stockholders have until the deadlines listed below...
Feb 17, 2019 08:04 am ET
CLASS ACTION UPDATE for AXGN, TYME and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 15, 2019 10:50 pm ET
AXOGEN SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AxoGen, Inc. - AXGN
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit against AxoGen, Inc. (NasdaqCM: AXGN), if they purchased the Company’s securities in connection with its November 2017 or May 2018 secondary public offering or between August 7, 2017 and December 18, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the Middle District of Florida.
Feb 15, 2019 05:00 pm ET
CLASS ACTION UPDATE for PRGO, AXGN, YRIV and W: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 15, 2019 03:17 pm ET
Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against AxoGen, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the March 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN) securities...
Feb 15, 2019 09:54 am ET
CLASS ACTION UPDATE for IMMU, DBVT, AXGN and MKL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 14, 2019 08:06 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AxoGen, Inc. (AXGN)
Law Offices of Howard G. Smith reminds investors of the March 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN) securities: (a)...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.